# SUV on 68Ga-DOTATATE PET/CT and Ki-67 Index in Neuro-Endocrine Tumors

> **NCT02840149** · PHASE3 · COMPLETED · sponsor: **Jewish General Hospital** · enrollment: 45 (actual)

## Conditions studied

- Neuroendocrine Tumors

## Interventions

- **DRUG:** 68Ga-DOTATATE PET/CT

## Key facts

- **NCT ID:** NCT02840149
- **Lead sponsor:** Jewish General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-10-01
- **Primary completion:** 2023-12-13
- **Final completion:** 2023-12-13
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2025-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02840149

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02840149, "SUV on 68Ga-DOTATATE PET/CT and Ki-67 Index in Neuro-Endocrine Tumors". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02840149. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*